Core Viewpoint - Axogen, Inc. has announced an upsized public offering of 4,000,000 shares of common stock priced at $31.00 per share, aiming to raise approximately $124 million before expenses [1][3]. Group 1: Offering Details - The public offering is set to close on January 23, 2026, pending customary closing conditions [2]. - Wells Fargo Securities and Mizuho are the lead book-running managers, with Canaccord Genuity and Raymond James serving as co-managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for early payoff and termination of a term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes [3]. Group 3: Regulatory Information - The offering is made under an automatic shelf registration statement on Form S-3ASR, effective upon filing with the SEC on January 21, 2026 [4]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available for free on their website [4]. Group 4: Company Overview - Axogen focuses on the development and commercialization of technologies for peripheral nerve repair, aiming to establish nerve repair as the standard of care [6]. - The company's product portfolio includes various nerve repair solutions such as Avance® and Axoguard® products [7].

ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it intends to offer and sell, subject to market and other conditions, $85.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Axogen intends to grant the underwriters a 30-day option to purchase up to an additional $12.75 millio ...

PresentationGood morning, everyone. Welcome, and thank you for joining us. My name is [indiscernible] I'm an associate in the health care group at JPMorgan. And today, I have the pleasure of introducing the Axogen team. Joining us today is President and CEO, Mike Dale, and we also have CFO, Lindsey Hartley with us. Just a quick reminder on format. This will be a 20-minute presentation followed by 20 minutes of Q&A. Before we start, just be advised that there will be a handheld mic being passed around during ...

AxoGen’s approach, which management referred to as the “Axogen algorithm,” is built around the Avance Nerve Graft, complemented by AxoGuard and Avive products intended to support healing and protect repairs. Dale described Avance as donated human tissue processed to be “immunologically benign” while remaining bioactive, retaining human laminin to support axon regeneration and Schwann cell infiltration.He framed peripheral nerve dysfunction as arising from injuries such as transection, crushing, or stretchin ...

AxoGen Conference Call Summary Company Overview - **Company**: AxoGen - **Industry**: Healthcare, specifically focused on peripheral nerve repair and restoration Core Points and Arguments 1. **Business Purpose**: AxoGen aims to restore peripheral nerve function to improve health and quality of life, addressing under-treatment in the healthcare sector [2][4][10] 2. **Market Opportunities**: The company identifies four clinical care pathways: extremities, breast reconstruction, oral maxillofacial, and prostate procedures, with significant growth potential in each area [4][10][16] 3. **Product Distinction**: The Avance Nerve Graft is highlighted as a unique solution, being the first approved biologic therapeutic for treating nerve discontinuities, which enhances nerve regeneration [5][8][29] 4. **Growth Projections**: AxoGen expects to grow its business by 15%-20% annually, driven by increased awareness and adoption of their products in various clinical pathways [9][24] 5. **Education and Training**: The company emphasizes education as a core competency, engaging with healthcare professionals to improve knowledge and skills in nerve care [12][13] 6. **Reimbursement Progress**: AxoGen has made strides in securing coverage for nerve care, with a goal to achieve full coverage by 2028, having added nearly 20 million covered lives recently [18][30] 7. **Operational Improvements**: Post-BLA approval, the company plans to streamline operations under a single quality system, enhancing efficiency and gross margins [32][33] 8. **Clinical Studies**: AxoGen is initiating large-scale clinical studies to further validate the effectiveness of their products, which will support market adoption and establish standard care practices [22][23] Additional Important Content 1. **Emerging Markets**: AxoGen is considering international expansion, focusing on markets with logical regulatory pathways and reimbursement systems [39][40] 2. **Sales Productivity**: New hires typically take 6-9 months to become productive, aligning with industry standards for med tech companies [35] 3. **Market Dynamics**: The company anticipates a shift towards outpatient procedures due to recent reimbursement changes, which could significantly alter the treatment landscape for nerve care [46][48] 4. **Long-term Vision**: AxoGen is committed to continuous improvement in R&D, aiming to enhance product capabilities and expand clinical applications [21][22] This summary encapsulates the key insights from the AxoGen conference call, highlighting the company's strategic direction, market opportunities, and operational focus.

Market Opportunity & Growth Strategy - The US nerve care market represents a large and underserved $56 billion opportunity[9] - Axogen is pursuing a strategic plan (2025-2028) with a revenue CAGR target of 15-20%[25, 72] - The company aims to achieve operational cash flow exceeding $60 million per year by the end of 2028[73] Clinical & Technological Leadership - Avance is the first FDA-approved biologic treatment for nerve discontinuities in patients aged one month and older[18] - Axogen has treated over 200,000 patients and has over 300 clinical and scientific publications supporting its nerve repair algorithm[26] - Allograft is increasingly preferred for nerve repair, with 41% preferring it for gaps >2cm in 2024[33] Reimbursement & Coverage - Approximately 35% of commercial lives remain uncovered, indicating an opportunity for expanded coverage[24, 46] - In FY25, 198 million lives were added across ten regional BCBS plans (182 million private; 16 million Medicare Advantage)[48] - New outpatient code group and Level 3 Nerve Procedure Code increases reimbursement for hospitals and ASC's[49] Financial Performance - Axogen's revenue has grown from $599 million in 2021 to $2252 million in 2025, representing a 149% 5-year CAGR[66, 67] - The company is expanding EBITDA, with projections of $198 million and $214 million for EBITDA and Adjusted EBITDA respectively in 2025[69]

Company Achievements - Axogen received FDA approval for its unique nerve graft on December 3, 2025, which is a human tissue-based product aimed at repairing damaged peripheral nerves without requiring nerve tissue from patients, granting the company 12 years of market exclusivity [1] - The company is expected to report approximately $225.2 million in annual revenue for FY 2025, marking its highest revenue to date [6] Stock Performance - Axogen's stock (AXGN) experienced a significant increase of 97.60% in 2025, with seven consecutive months of price gains [2] - CEO Michael D. Dale sold 25,000 shares on December 10, 2025, valued at $750,000, which represented 28.24% of his direct holdings prior to the transaction [5] Product and Market Focus - Axogen specializes in surgical solutions for peripheral nerve injuries, developing biologically active nerve grafts, nerve connectors, nerve protectors, nerve caps, and soft tissue membranes for surgical repair and protection of peripheral nerves [3]

Market Opportunity - The total addressable market (TAM) for nerve care in the US is estimated at $5.6 billion, with over 1.5 million peripheral nerve injuries requiring treatment annually[4] - The total addressable market (TAM) is estimated at $5.6 billion with minimal current penetration[25] - Approximately 60% of nerve injuries go undiagnosed prior to patient discharge, indicating a substantial opportunity for market development and patient awareness initiatives[8] - The company has identified four distinct market opportunities at different stages of development[25] Financial Projections - Axogen expects a revenue compound annual growth rate (CAGR) of 15% to 20% from 2025 to 2028, with gross margin improvements anticipated due to process enhancements[24] - The company aims to achieve operational cash flow exceeding $60 million per year by the end of 2028, with a focus on self-funding organic growth initiatives and debt repayment[24] - Positive cash flow is expected, with expanding margins and accelerating growth[25] Reimbursement and Regulatory Changes - In 2026, the Centers for Medicare & Medicaid Services (CMS) will introduce a new outpatient code group, increasing reimbursement for hospitals and ambulatory surgery centers by approximately 40% year-over-year[18] - There are reimbursement tailwinds with expanding coverage and improving payment rates[25] Product Development and Market Strategy - Axogen's Avance® product is the first FDA-approved biologic treatment for nerve discontinuities, with a significant clinical evidence base supporting its use[7] - The company has three active development projects aimed at expanding its product offerings, including new clinical applications for prostate surgery[19] - Axogen's strategic plan includes continuous optimization of the business model and customer creation processes, focusing on elective and planned procedures[9] - The company has a proven commercial model ready to capture market share[25] Customer Reach and Sales Channels - The company has treated over 200,000 patients and has established access in more than 2,700 hospitals and outpatient centers, supported by a large direct sales channel[10]

ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and full-year 2025 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter 2025 revenue is expected to be approximately $59.9 million, which represents a 21.3% increase over the fourth quarter of 2024, ...

Core Insights - Axogen, Inc. is a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function [1] - The company will participate in the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, at 10:30 AM Pacific Standard Time [2] Company Overview - Axogen focuses on the science, development, and commercialization of technologies for peripheral nerve repair, aiming to make nerve repair the expected standard of care [3] - The company's product portfolio includes Avance® (acellular nerve allograft-arwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™ [4] - Axogen's products are available in multiple countries, including the United States, Canada, Germany, the United Kingdom, and Spain [4]